The allosteric inhibitor asciminib shows clinical activity in heavily pretreated patients with chronic myeloid leukaemia who have failed or cannot tolerate tyrosine kinase inhibitors, including those who do not respond to ponatinib and harbour a T315I mutation, according to the results of a phase I dose-escalation study.
The risk of gastric cancer in patients cured of Helicobacter pylori appears to be greater in the second decade of follow-up than in the prior 10-year period, with the risk being specific to diffuse-type of disease among those with mild-to-moderate gastric atrophy, a study has reported.
An artificial intelligence (AI) system can predict breast cancer in mammograms better than a radiologist, with results holding across two large datasets that are representative of different screening populations and practices, as shown in a recent study. This highlights the technology’s potential to enhance the efficiency of breast cancer diagnosis.
The addition of the potent triple angiokinase inhibitor nintedanib to a standard chemotherapeutic regimen consisting of gemcitabine and cisplatin generated survival benefit in patients with locally advanced muscle invasive bladder cancer (MIBC), according to the results of the NEO-BLADE* trial presented at ASCO GU 2020. However, the study failed to demonstrate improvement in the primary endpoint of pathologic complete response (CR).
The recently published phase III POUT* trial demonstrated that adjuvant gemcitabine-platinum chemotherapy after nephroureterectomy boosts disease free-survival (DFS) in patients with locally advanced upper urinary tract urothelial carcinoma (UTUC).
The American Society of Clinical Oncology (ASCO) is collecting and answering questions on caring for cancer patients in the context of the coronavirus disease 2019 (COVID-19) pandemic. The first set of frequently asked questions (FAQs), published recently, sheds light on the risk of COVID-19 and its complications in cancer patients, and addresses issues pertinent to the care of cancer patients and decisions on treatment.
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.